

Pazopanib in sarcoma monitoring algorithm

Baseline assessment:

- FBC, U&Es, LFTs (including γ GT, AST, and thyroid function), urine (protein)
- Check blood pressure and weight
- Echocardiogram or MUGA scan, ECG
- CT/MRI scan
- Contraception advice – childbearing age
- Consent for Pazopanib treatment
- CDF application (email - Oncology Pharmacy)

Start at **800 mg daily** if good Performance Status

Consider starting at lower dose if poorer PS and escalating subsequently

For moderate hepatic impairment: recommended dose is 200mg once daily (refer to SPC)

Cycle 1:

- See day 1, 15, 29 (post week 2 and 4)
- Blood tests: FBC, U&Es, LFTs (including γ GT and AST), urine (protein)
- Check blood pressure and weight
- CNS Follow-up (telephone consultation) day 7 – i.e. borderline BP
- Book Echocardiogram or MUGA, ECG for 3 months after starting treatment
- For the first assessment book CT/MRI scan at clinician discretion

Cycle 2:

- See day 57 (post week 8)
- Blood tests: FBC, U&Es, LFTs (including γ GT and AST), urine (protein)
- Check weight
- Check blood pressure weekly

Cycles 3 and 4:

- Monitor every 4 weeks as above

After cycle 4:

- Monitor every 4 – 6 weeks

Prior to cycle 4 (week 12): CT/MRI response assessment, Echocardiogram or MUGA, ECG, thyroid function and urinalysis then repeat every 12 weeks or as indicated.

FILE NAME	Pazopanib monitoring algorithm	PAGE NO	1	DATE	February 2015
AUTHOR	Palma Dileo and Charlotte Benson	VERSION NO	1	AUTHORISED BY	SAG